CN115109713B - 用于缓解外伤性口腔病变的益生菌及生物制剂 - Google Patents
用于缓解外伤性口腔病变的益生菌及生物制剂 Download PDFInfo
- Publication number
- CN115109713B CN115109713B CN202210218751.5A CN202210218751A CN115109713B CN 115109713 B CN115109713 B CN 115109713B CN 202210218751 A CN202210218751 A CN 202210218751A CN 115109713 B CN115109713 B CN 115109713B
- Authority
- CN
- China
- Prior art keywords
- probiotics
- lactobacillus reuteri
- use according
- oral
- biological agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003124 biologic agent Substances 0.000 title claims abstract description 18
- 239000006041 probiotic Substances 0.000 title claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 16
- 230000000472 traumatic effect Effects 0.000 title claims abstract description 14
- 208000025157 Oral disease Diseases 0.000 title claims abstract description 11
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 23
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 23
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 229920001202 Inulin Polymers 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- 239000007968 orange flavor Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000008939 whole milk Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 12
- 208000002064 Dental Plaque Diseases 0.000 abstract description 3
- 208000007117 Oral Ulcer Diseases 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 2
- 238000012937 correction Methods 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 230000036407 pain Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 241001052560 Thallis Species 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010031009 Oral pain Diseases 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 4
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007944 soluble tablet Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
序号 | 程度 | 描述 |
0 | 无疼痛 | 无痛感,可以较好生活与睡眠。 |
1 | 轻度疼痛 | 有痛感,但能忍受,能正常生活与睡眠。 |
2 | 中度疼痛 | 痛感明显,且稍许影响睡眠,需要止痛药。 |
3 | 重度疼痛 | 痛感较强,影响睡眠,需要麻醉止痛。 |
4 | 剧烈疼痛 | 痛感强,影响睡眠较严重,伴有其它症状。 |
5 | 不能忍受 | 严重影响睡眠,伴有其它症状,包括被动体位。 |
罗伊氏乳杆菌组,10人 | 安慰剂组,10人 | p | |
女性,数量 ,(百分比) | 7(70) | 6(60) | 0.999 |
平均年龄,(范围) | 28.1±13.3 (14-57) | 27.5±9.1(15-45) | 0.907 |
身体质量指数,平均数 | 21.4±2.6 | 23.1±3.3 | 0.23 |
金属器具,数量(百分比) | 9(90) | 9(90) | 0.999 |
罗伊氏乳杆菌组,10人 | 安慰剂组,10人 | p | |
口腔损伤,平均天数 | 2.5±1.0 | 4.9±3.0 | 0.018 |
口腔疼痛评分,中间值 | 0(0-4) | 3(0-5) | 0.039 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210218751.5A CN115109713B (zh) | 2022-03-08 | 2022-03-08 | 用于缓解外伤性口腔病变的益生菌及生物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210218751.5A CN115109713B (zh) | 2022-03-08 | 2022-03-08 | 用于缓解外伤性口腔病变的益生菌及生物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115109713A CN115109713A (zh) | 2022-09-27 |
CN115109713B true CN115109713B (zh) | 2023-10-31 |
Family
ID=83324514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210218751.5A Active CN115109713B (zh) | 2022-03-08 | 2022-03-08 | 用于缓解外伤性口腔病变的益生菌及生物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115109713B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991429A (zh) * | 2020-08-19 | 2020-11-27 | 湖南天根乐微君科技有限公司 | 罗伊氏乳杆菌在制备抗口腔细菌感染的制品中的应用 |
CN113181253A (zh) * | 2021-05-11 | 2021-07-30 | 菌联肽康(山东)医药有限公司 | 一种杀灭幽门螺旋杆菌的复合益生菌制剂及制备方法 |
-
2022
- 2022-03-08 CN CN202210218751.5A patent/CN115109713B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991429A (zh) * | 2020-08-19 | 2020-11-27 | 湖南天根乐微君科技有限公司 | 罗伊氏乳杆菌在制备抗口腔细菌感染的制品中的应用 |
CN113181253A (zh) * | 2021-05-11 | 2021-07-30 | 菌联肽康(山东)医药有限公司 | 一种杀灭幽门螺旋杆菌的复合益生菌制剂及制备方法 |
Non-Patent Citations (3)
Title |
---|
Effect of probiotic lozenges containing Lactobacillus reuteri on oral wound healing: a pilot study;S. Twetman 等;Beneficial Microbes;1-6 * |
Probiotic Lactobacillus reuteri has antifungal effects on oral Candida species in vitro;Jorgensen M.R.等;Journal of Oral Microbiology;第9卷(第1期);1-8 * |
一株罗伊氏乳杆菌的生物学特性研究;邵景海 等;中国乳品工业;第40卷(第3期);28-30 * |
Also Published As
Publication number | Publication date |
---|---|
CN115109713A (zh) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7846711B2 (en) | Lactobacillus strains and uses thereof | |
CN111560331B (zh) | 一株副干酪乳杆菌及其应用 | |
EP0880354A1 (en) | Urogenital and intestinal compositions | |
CN113957006B (zh) | 一种植物乳杆菌n13及其在预防或治疗龋齿和牙周炎上的应用 | |
CN110791452A (zh) | 一株改善口腔健康的唾液乳杆菌jyls-372及产品和制备方法 | |
CN113832062B (zh) | 一种副干酪乳杆菌lc86及其在预防或治疗龋齿和牙周炎上的应用 | |
CN116731891B (zh) | 一株短双歧杆菌b2798及其制备益生菌制剂的用途 | |
KR102084973B1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 | |
CN114574406B (zh) | 鼠李糖乳杆菌菌株wka55及其在制备防治酒精性肝损伤制品方面的用途与产品 | |
CN114958650A (zh) | 一种防治幽门螺杆菌感染的副干酪乳杆菌及其组合物与应用 | |
CN115153026A (zh) | 鼠李糖乳杆菌菌株LRa05在制备抑制幽门螺杆菌和/或变异链球菌制品方面的用途 | |
CN109527099A (zh) | 一种枸杞复合益生菌羊奶片及其制备方法 | |
CN111685328B (zh) | 那曲4580及其制剂在调节情绪的食品中的应用 | |
JP6261688B2 (ja) | Qol改善又は持続剤 | |
CN115109713B (zh) | 用于缓解外伤性口腔病变的益生菌及生物制剂 | |
US20230346856A1 (en) | Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof | |
JPWO2019151371A1 (ja) | 肺炎球菌感染症の予防及び/又は治療剤 | |
CN115518080A (zh) | 乳双歧杆菌BLa80在改善和缓解过敏反应上的应用 | |
CN113041266B (zh) | 一株改善银屑病样小鼠病理特征的干酪乳杆菌及其应用 | |
CN115404185A (zh) | 一种拮抗白色念珠菌的卷曲乳杆菌lcp051及其应用 | |
CN107441121A (zh) | 一种唾液链球菌的发酵粗提物及其制备方法和应用 | |
CN116024128B (zh) | 一株嗜热链球菌菌株p0012及其制备的口腔健康护理用益生菌组合物和应用 | |
CN115624572A (zh) | 可干预代谢综合征的短双歧杆菌ccfm683及应用 | |
CN118256375A (zh) | 一株用于调节血压及糖脂代谢的罗伊氏粘液乳杆菌及其应用 | |
JP2023072623A (ja) | 過活動膀胱関連症状の緩和用の複合プロバイオティクス組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 10666 Songze Avenue, Qingpu District, Shanghai, 201700 Applicant after: Biogrowing. Co.,Ltd. Address before: 10666 Songze Avenue, Qingpu District, Shanghai, 201700 Applicant before: BIOGROWING (SHANGHAI) Co.,Ltd. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiang Deyi Inventor after: Zheng Jianfeng Inventor after: Han Di Inventor after: Song Jinan Inventor after: Tian Lulu Inventor before: Jiang Deyi Inventor before: Zheng Jianfeng Inventor before: Han Di Inventor before: Tian Lulu Inventor before: Song Jinan |
|
GR01 | Patent grant | ||
GR01 | Patent grant |